← Back to headlines
Nuvation Bio and Eisai's Taletrectinib Application for NSCLC Accepted by EMA
The European Medicines Agency (EMA) has accepted the application from Nuvation Bio and Eisai for taletrectinib, a drug intended for the treatment of non-small cell lung cancer (NSCLC).
26 Mar, 21:26 — 26 Mar, 21:26
Sources
Showing 1 of 1 sources
Related Stories
PhilHealth Launches Online Tool for Member Records Verification
just now
Noelia Castillo Ramos, 25, receives euthanasia after two-year process
16m ago
Data is the New Gold in Science: AI in Medicine Requires Secure Patient Data
19m ago
Experts Discuss Irritable Bowel Syndrome Symptoms, Treatment, and Management
20m ago